BeOne Medicines Ltd. (ONC) Research

BeOne Medicines Ltd. (ONC), initially founded in 2010 as BeiGene, stands as a prominent global oncology enterprise committed to identifying, advancing, and bringing to market cutting-edge cancer treatments. The company underwent a significant transformation, rebranding as BeOne in late 2024 and subsequently relocating its headquarters from Cambridge, Massachusetts, to Basel, Switzerland, in 2025. With a vast operational footprint extending across more than 45 countries and six continents, BeOne has firmly established itself as a leader in both immuno-oncology and targeted therapy solutions. Its strong product lineup includes key assets such as Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved worldwide for a variety of cancer types, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that has surpassed $1.3 billion in annual revenue and is approved in major regions like the U.S., Europe, and China. BeOne's strategic foundation combines proprietary research and development efforts with the integration of compounds obtained through external alliances, thereby fueling a comprehensive pipeline addressing both blood cancers and solid tumors.

Market snapshot

Symbol
ONC
Price
$270.15
Day change
+2.84%
Market cap
$33.7B
P/E ratio
4.01x
52-week range
239.25-385.22
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Next earnings
in 1 month
Analyst price target
$399.11

Recent news

  • Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

    Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients ​live 15% longer than BeOne Medicines' Tevimbra immunotherapy.

  • BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer

    The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval to BeOne Medicines Ltd.‘s (NASDAQ:ONC) Beqalzi (sonrotoclax) for adults with relapsed or refractory mantle cell lymphoma who previously received at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor.

Peer companies

  • Agilent Technologies, Inc. (A)
  • Alcon Inc. (ALC)
  • GE HealthCare Technologies Inc. (GEHC)
  • Humana Inc. (HUM)
  • Insmed Incorporated (INSM)
  • IQVIA Holdings Inc. (IQV)
  • Mettler-Toledo International Inc. (MTD)
  • Natera, Inc. (NTRA)

Recent insider activity

  • Wu Xiaobin — S-Sale (1357 shares) on 2026-06-16
  • OYLER JOHN — S-Sale (1650 shares) on 2026-06-16
  • OYLER JOHN — S-Sale (1710 shares) on 2026-06-16
  • OYLER JOHN — S-Sale (333 shares) on 2026-06-16
  • Lee Chan Henry — S-Sale (590 shares) on 2026-06-16

Open BeOne Medicines Ltd. (ONC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.